Shama Parveen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shama Parveen has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Monisha Banerjee
Molecular and Human Genetics Laboratory, Department of Zoology, University of Lucknow, Lucknow 226007, Uttar Pradesh, India
1 shared publication - Osaid Masood
Molecular and Human Genetics Laboratory, Department of Zoology, University of Lucknow, Lucknow 226007, Uttar Pradesh, India
1 shared publication - Prince Kumar Singh
The Institute for Drug Research, The School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel
1 shared publication - Saurabh Kumar
Department of Zoology University of Lucknow Lucknow India
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (11) , 1206
Plant-Derived Bioactive Compounds in Chronic Obstructive Pulmonary Disease: Targeting Oxidative Stress and Inflammatory Signaling
Chronic obstructive pulmonary disease (COPD) is characterised by persistent airflow limitation arising from chronic inflammation, oxidative stress, mucus hypersecretion, protease–antiprotease imbalance, airway remodelling, and emphysematous destruction. This review evaluates plant-derived bioactive compounds with reported activity against molecular processes implicated in COPD. Resveratrol, kaempferol, quercetin, fisetin, epigallocatechin gallate, gallic acid, ursolic acid, hesperidin, apigenin, and luteolin are examined with emphasis on Nrf2, NF-κB, MAPKs, PI3K/Akt, SIRT1, TLR4, and NLRP3 signalling. In selected cellular and animal models, these compounds have been reported to reduce oxidative stress, inflammatory mediator release, mucus production, metalloproteinase activity, and tissue injury. However, these experimental findings do not establish therapeutic efficacy in patients with COPD. Some also affect autophagy, corticosteroid sensitivity, and pathways associated with cellular senescence. Overall, the evidence is derived mainly from cultured cells and animal models, with limited clinical data. Poor oral bioavailability, rapid metabolism, uncertain pulmonary exposure, formulation variability, dose standardisation, and potential drug interactions remain major translational limitations. Future studies should define pharmacokinetics, lung tissue exposure, optimal formulations, safety, and interactions with standard COPD therapies, followed by adequately powered clinical trials assessing exacerbations, lung function, symptoms, exercise capacity, quality of life, and treatment-related adverse effects in well-defined COPD populations.
- 12 November 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (11) , 1206
Open AccessPlant-Derived Bioactive Compounds in Chronic Obstructive Pulmonary Disease: Targeting Oxidative Stress and Inflammatory Signaling
Chronic obstructive pulmonary disease (COPD) is characterised by persistent airflow limitation arising from chronic inflammation, oxidative stress, mucus hypersecretion, protease–antiprotease imbalance, airway remodelling, and emphysematous destruction. This review evaluates plant-derived bioactive compounds with reported activity against molecular processes implicated in COPD. Resveratrol, kaempferol, quercetin, fisetin, epigallocatechin gallate, gallic acid, ursolic acid, hesperidin, apigenin, and luteolin are examined with emphasis on Nrf2, NF-κB, MAPKs, PI3K/Akt, SIRT1, TLR4, and NLRP3 signalling. In selected cellular and animal models, these compounds have been reported to reduce oxidative stress, inflammatory mediator release, mucus production, metalloproteinase activity, and tissue injury. However, these experimental findings do not establish therapeutic efficacy in patients with COPD. Some also affect autophagy, corticosteroid sensitivity, and pathways associated with cellular senescence. Overall, the evidence is derived mainly from cultured cells and animal models, with limited clinical data. Poor oral bioavailability, rapid metabolism, uncertain pulmonary exposure, formulation variability, dose standardisation, and potential drug interactions remain major translational limitations. Future studies should define pharmacokinetics, lung tissue exposure, optimal formulations, safety, and interactions with standard COPD therapies, followed by adequately powered clinical trials assessing exacerbations, lung function, symptoms, exercise capacity, quality of life, and treatment-related adverse effects in well-defined COPD populations.